Is It The End For OncoGenex? Custirsen Fails In Second Phase III Prostate Cancer Trial
Custirsen, the lead drug candidate from OncoGenex, failed in a second Phase III clinical trial – a trial that may have represented the company's last, best hope of success.
You may also be interested in...
Deal Watch: Taking Care Of Business Before J.P. Morgan
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
Does CheckMate 026 Take Bristol Out Of The End Game?
Failure of Bristol's Opdivo in patients with lower expression of PD-L-1 biomarker gives Merck's Keytruda a huge advantage in first-line lung cancer, and leaves market-leading Bristol to wait for combination data.
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
By granting an approval four months ahead of schedule of Roche AG's and Genentech Inc.'s anti-PD-LI cancer immunotherapy Tecentriq (atezolizumab), the FDA may have helped the companies secure a better lead in the bladder cancer marketplace than the firms otherwise would have held. But already established immunotherapies, Merck & Co. Inc.'s Keytruda (pembrolizumab) and Bristol-Myer Squibb Co.'s Opdivo (nivolumab), are in hot pursuit.